Brain metastasis as initial presentation of lung cancer - Impact of prognostic factors on patient survival
Background: Brain metastasis (BM) in patients with cancer is a predictor of poor prognosis and is present at initial diagnosis in 15-30% of lung cancer patients.Methods: A retrospective analysis for a period of 27 years (1989-2016) identified patients with confirmed diagnosis of lung cancer and BM at presentation.Results: 192 patients were included, 98 (51%) had brain as the only site of metastatic disease. The mean age was 62.4±11.1 years and 163 (84.9%) were male patients. Thirty (31.3%) patients had solitary metastasis and 132 (68.8%) multiple metastasis. Therapeutic modalities for BM were: whole-brain radiation therapy (132, 68.8%), radiotherapy plus surgery (8, 4.2%), surgery (7, 3.6%), radiosurgery (1, 0.5%) and no treatment (44, 22.9%). Median survival was 3.7 months.Sixty-two (32.2%) patients received palliative chemotherapy and 118 (61.5%) best supportive care. Median survival in patients who received chemotherapy was 4.7 vs. 2 months in patients who didn’t receive (p
Conclusion In the second-line or later-line treatment, bevacizumab combined with chemotherapy is an effective and safe regimen for advanced non-squamous NSCLC. DOI: 10.3779/j.issn.1009-3419.2018.07.02
Conventional whole brain radiotherapy (WBRT) has been established as the treatment standard in patients with cerebral metastases from small-cell lung cancer (SCLC), however, it has only modest efficacy and lim...
CONCLUSIONS: The FU program did not identify the majority of patients with IBR. Including cerebral imaging in the FU program may result in an earlier detection of brain metastases. These matters should be studied in a prospective setting. PMID: 30010453 [PubMed - as supplied by publisher]
DiscussionRecent evidence suggests that SRS might be a promising treatment option for SCLC patients with brain metastases. The present trial is the first to prospectively investigate the treatment response, toxicity and neurocognition of WBRT and SRS in SCLC patients.Trial registrationClinicaltrials.govNCT03297788. Registered September 29, 2017.
Conclusions: WBRT remains the cornerstone of the management of brain metastases. The present study concludes that the survival of patients with brain metastases is significantly improved with female gender, good PS, primary breast cancer, time lag of>6 months between diagnosis of the primary tumor and development of brain metastases, solitary lesion, and controlled primary tumor.
ConclusionsThe mortality risk is highest with MOM and liver metastasis followed by bone, brain, other organ, and lung metastases in NSCLC and AD which is the most common variant for NSCLC. These results will be helpful for pre-treatment evaluation regarding the prognosis of NSCLC patients.
CONCLUSIONS: The mortality risk is highest with MOM and liver metastasis followed by bone, brain, other organ, and lung metastases in NSCLC and AD which is the most common variant for NSCLC. These results will be helpful for pre-treatment evaluation regarding the prognosis of NSCLC patients. PMID: 30003315 [PubMed - as supplied by publisher]
Publication date: June 2018Source: Pharmacology &Therapeutics, Volume 186Author(s): Myth T. Mok, Jingying Zhou, Wenshu Tang, Xuezhen Zeng, Antony W. Oliver, Simon E. Ward, Alfred S. ChengAbstractCyclin-dependent kinase 20 (CDK20), or more commonly referred to as cell cycle-related kinase (CCRK), is the latest member of CDK family with strong linkage to human cancers. Accumulating studies have reported the consistent overexpression of CCRK in cancers arising from brain, colon, liver, lung and ovary. Such aberrant up-regulation of CCRK is clinically significant as it correlates with tumor staging, shorter patient surviva...
Authors: Sasano H, Sekine A, Hirata T, Iwamoto K, Itou Y, Itani H, Kondou S, Tokui T, Tanigawa M Abstract We herein report a 37-year-old woman with lung adenocarcinoma with brain metastases and an asymptomatic ovarian tumor. Immunohistochemistry and a fluorescent in situ hybridization analysis of the biopsied lung tumor revealed ALK gene rearrangement. Although the origin of the ovarian tumor remained unclear, alectinib administration was initiated, and radiological responses were observed in all lesions, which confirmed that the ovarian tumor was a metastasis from lung cancer. Although differentiating the origin o...
(University of Colorado Anschutz Medical Campus) Brain metastases were found to be fairly common in stage IV ROS1-positive cancers and in 47 percent of ROS1 patients, the brain was the first and only site of progression.